TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03916861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioelectrical Impedance Analysis
Description: We use Inbody S20 analysis to measure fluid status before each hemodialysis session to guide fluid removal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physician-guided
Description: This intervention used physical examination as guided to adjust fluid therapy together with the chart record of intake and output per day
Study: NCT04449315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Young Living Lavender Essential Oil
Description: For qualified patients one to two drops of hospital approved essential oil will be placed on a 4X4 gauze and will be offered to the patient during their infusion visit. This gauze will be placed in a sealable clear plastic bag and the patient will be instructed to use one sniff at a time.
Study: NCT01686386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase I: dose escalation of Bendamustine Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase I: dose escalation of Lenalidomide Phase II: Dexamethasone will be given in combination with the Maximum Tolerated Dose (MTD) of Bendamustine and Lenalidomide in cycles lasting 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Phase I and Phase II Dexamethasone fixed dose 40 mg/die
Study: NCT01906918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IRPC, Remote preconditioning
Description: The patients will be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion. This cycle will be repeated 4 times.
Study: NCT04991194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: Each subject was administered either 1200 mg (Part 1) or 400 mg (Part 2) BIA 5-1058 od for 10 days, in fasting conditions for 8 hours \[Day (D)2 to D9\] or 10 hours (D1 and D13), and remained fasted for 2 hours (D2 to D9) or 4 hours (D1 and D13) post-dose. The formulation was tablets 100 mg and the mode of administration was oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: Each subject was administered either 1200 mg (Part 1) or 400 mg (Part 2) BIA 5-1058 od for 10 days, in fasting conditions for 8 hours \[Day (D)2 to D9\] or 10 hours (D1 and D13), and remained fasted for 2 hours (D2 to D9) or 4 hours (D1 and D13) post-dose. The formulation was tablets 100 mg and the mode of administration was oral.
Study: NCT01555645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management, in two steps
Description: All patients start at the first step of the intervention program with a two hours psychoeducation in stress management. Patients, who don't report a decrease in stress related symptoms, after the first step will be offered an intensive stress management, either in individual or group format. Components included in the intervention concern 1) basic knowledge about cancer, treatment, healthy living and stress reactions, 2) self-awareness with help of diary for thoughts, feelings and behavior 3) instruction in various techniques on how to express negative feelings, how to communicate with others more effectively, how to change behaviors related to stress 4) training these techniques in real-life situations 5) cognitive restructuring 6) spirituality, derived from cognitive behavior therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management, in two steps
Description: All patients start at the first step of the intervention program with a two hours psychoeducation in stress management. Patients, who don't report a decrease in stress related symptoms, after the first step will be offered an intensive stress management, either in individual or group format. Components included in the intervention concern 1) basic knowledge about cancer, treatment, healthy living and stress reactions, 2) self-awareness with help of diary for thoughts, feelings and behavior 3) instruction in various techniques on how to express negative feelings, how to communicate with others more effectively, how to change behaviors related to stress 4) training these techniques in real-life situations 5) cognitive restructuring 6) spirituality, derived from cognitive behavior therapy.
Study: NCT03525522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG Laser
Description: Three sessions of Nd:YAG treatment every two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroid Diprosone
Description: 3 months of topical corticosteroids Diprosone
Study: NCT04308850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D drops
Description: Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
Study: NCT01931722

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Branched chain amino acid
Description: seven graded intakes of a BCAA (branched chain amino acid) mixture from 50 to 350 mg.kg-1.d-1 will be used to measure BCAA requirement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Branched chain amino acid
Description: seven graded intakes of a BCAA (branched chain amino acid) mixture from 50 to 350 mg.kg-1.d-1 will be used to measure BCAA requirement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1 repetition maximum (maximum weight that can be lifted only one time). Instruction will be provided for all exercises and professional trainers will oversee all training sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1 repetition maximum (maximum weight that can be lifted only one time). Instruction will be provided for all exercises and professional trainers will oversee all training sessions.
Study: NCT04673201

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Viscotrabeculotomy Versus trabeculectomy with MMC
Description: Viscotrabeculotomy involved the creation of a partial thickness scleral flap, followed by localization of Schlemm's canal by radial incisions.High viscosity sodium hyaluronate was injected into Schlemm's canal.Trabeculotomy was completed using the standard metal Harm's trabeculotome.The scleral flap was then secured and conjunctival closure ensued.Trabeculectomy technique involved a creation of a limbal-based conjunctival flap, followed by creation of a half-thickness sclera flap. MMC was applied underneath the conjunctival flap.The procedure was completed with both sclera and conjunctiva closed by 10/0 nylon sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Viscotrabeculotomy Versus trabeculectomy with MMC
Description: Viscotrabeculotomy involved the creation of a partial thickness scleral flap, followed by localization of Schlemm's canal by radial incisions.High viscosity sodium hyaluronate was injected into Schlemm's canal.Trabeculotomy was completed using the standard metal Harm's trabeculotome.The scleral flap was then secured and conjunctival closure ensued.Trabeculectomy technique involved a creation of a limbal-based conjunctival flap, followed by creation of a half-thickness sclera flap. MMC was applied underneath the conjunctival flap.The procedure was completed with both sclera and conjunctiva closed by 10/0 nylon sutures.
Study: NCT03979768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes risk assessment service in Norwegian community pharmacies
Description: Two pharmacists at each pharmacy were trained to perform risk assessments and counselling. During six months, pharmacy customers equal or above 45 years old, wishing to participate contacted the pharmacy staff. Participants completed a validated diabetes risk test and a background questionnaire including a validated instrument for self-rated health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes risk assessment service in Norwegian community pharmacies
Description: Two pharmacists at each pharmacy were trained to perform risk assessments and counselling. During six months, pharmacy customers equal or above 45 years old, wishing to participate contacted the pharmacy staff. Participants completed a validated diabetes risk test and a background questionnaire including a validated instrument for self-rated health.
Study: NCT02807987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150
Description: CS-3150 1.25 to 2.5, 5mg, orally
Study: NCT04034290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamFluVac
Description: The drug is a vaccine that induces high-level immunity against influenza A viruses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamFluVac
Description: The drug is a vaccine that induces high-level immunity against influenza A viruses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamFluVac
Description: The drug is a vaccine that induces high-level immunity against influenza A viruses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01526174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections
Study: NCT04512781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Cannula - Prosoft Cannula - Unicorn Cannula
Description: The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Cannula - Unicorn Cannula - Prosoft Cannula
Description: The purpose of this intervention is to evaluate the efficacy of a conventional legacy cannula design to provide targeted relief of dyspnea. The purpose of this intervention is to evaluate the efficacy of a next generation cannula to provide relief of dyspnea.
Study: NCT02723981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COMBO-Stent
Description: The OrbusNeich COMBO Bio-engineered Sirolimus Eluting Stent (COMBO Stent) consists of a 316L stainless steel alloy abluminally coated with a biocompatible, biodegradable poly-mer containing sirolimus. Covalently attached to the surface of the stent is a layer of murine, monoclonal, anti-human CD34 antibody. The antibody specifically targets circulatory CD34+ cells (endothelial progenitor cells) thus favoring endothelialization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran
Description: Anticoagulant medication after stent Implantation: (N)OAC and clopidogrel for 3 months followed by (N)OAC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Any drug eluting stent oder bare metal sent
Description: Implantation of traditional bare metal stents and/or drug eluting stents (any device approved on the market, implanted according to CE marking and IFU) and medication regimen in accordance with ESC Guidelines
Study: NCT02862275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT02723981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran
Description: A combination of antiplatelet and anticoagulant therapy according to ESC guidelines (2014)
Study: NCT00804856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).
Study: NCT03604978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT04438421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Subjects will then be given Chlorhexidine 0.2%mouthwash, as an active comparator, to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
Study: NCT03604978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT04438421

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will then be given a placebo product to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
Study: NCT03754153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balanced Binocular Viewing (BBV)
Description: The dose of BBV therapy will be one hour a day or 2x30 min/day (depending on child's attention span and/or need to implement the treatment around the family daily routine).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy - Occlusion (patching) or blurring (atropine)
Description: The prescribed dose of occlusion treatment / patching (parental choice) will depend on the severity of amblyopia, as by current clinical practice based on PEDIG studies
Study: NCT03604978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo brain MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo brain MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo multi-fraction stereotactic radiosurgery
Study: NCT01883570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training in visual search strategy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: access to a library of chest x-rays without search strategy
Study: NCT03615027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dementia-specific advance care planning
Description: see detailed description
Study: NCT01400646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One tablet once daily for 5 days (Treatment Period 1, Days 1-7).
Study: NCT03604978

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo multi-fraction stereotactic radiosurgery
Study: NCT02360839

Intervention type: DEVICE
Group type: OTHER
Intervention: EUS-guided fine needle biopsy sampling (EUS-FNB)
Description: Dual sampling with EUS-FNA and EUS-FNB in a randomized order.
Study: NCT01400646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Type=exact number, unit mg, number=10, form=tablet , route=oral use. One tablet for 2-4 days (Treatment Period 1, Day 6 up to Day 11).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: Type=exact number, unit=mg, number=1, form=oral solution, route=oral use. 1 mg dose for 1 day (Treatment Period 1, Day 12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: Type=exact number, unit=mg, number=5, form=oral solution, route=oral use. 5 mg dose for 1 day (Treatment Period 2, Day 7).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Type-exact number, unit=mg, number=10, form=tablet, route=oral use. Tablet(s) administered once daily for 2-4 days (Treatment Period 2, Day 1 up to Day 6)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 2).
Study: NCT02712502

Intervention type: DRUG
Intervention: Levofloxacin
Description: * Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~* Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary.

Intervention type: DRUG
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary.
Study: NCT03366714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal CPAP support with RAM cannula
Description: Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support RAM cannula.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal CPAP support with Hudson cannula
Description: Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support Hudson cannula.
Study: NCT03394495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCE Combination group
Description: The combination intervention programme consists of a weekly exercise training sessions and 6 sessions of Behavioral Change Enhancement (BCE) programme.
Study: NCT02366962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7374
Description: subcutaneous
Study: NCT01994343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global posture reeducation
Description: An assessment of the women is performed using global posture reeducation.
Study: NCT03797287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tensor Tunnler
Description: Create the bone tunnels during the arthroscopic rotator cuff repair procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anchor Rotator Cuff Repair
Description: The suture anchors (Smith and Nephew PEEK Helicoil Anchor) are inserted in bone and the sutures are then used to sew the tendons to bone arthroscopically.
Study: NCT01051739

Intervention type: PROCEDURE
Intervention: Comparison of four visual field testing strategies
Description: We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.

Intervention type: PROCEDURE
Intervention: Comparison of four visual field testing strategies
Description: We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
Study: NCT03489213

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: Participants randomized to the DGA/AICR group will receive plant-based diet education, garden access and health coaching for 5 months. The sessions are offered every other week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Participants randomized to the DGA/AICR group will receive plant-based diet education, garden access and health coaching for 5 months. The sessions are offered every other week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Participants will wear a FitBit every day and monitor daily physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participants will wear a FitBit every day and monitor daily physical activity.
Study: NCT00804856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Description: Volasertib administered by Intravenous Infusion (IV) over 60 minutes on Days 1 and 15 (28-day cycle).